ABCB1 and GST polymorphisms associated with TP53 status in breast cancer

Pharmacogenetics and Genomics

Volumn 17, Issue 2, 2007, Pages 127-136

  Nordgard, Silje H ^a,b   Ritchie, Marylyn D ^e   Jensrud, Sigrid D ^a   Motsinger, Alison A ^e   Alnæs, Grethe I G ^a   Lemmon, Gordon ^d   Berg, Marianne ^a   Geisler, Stephanie ^c,d   Moore, Jason H ^f   Lønning, Per Eystein ^c,d   Børresen Dale, Anne Lise ^a,b   Kristensen, Vessela N ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

ABCB1; Breast cancer; Doxorubicin; Glutathione S transferase; Haplotype; MDR1; Single nucleotide polymorphism; TP53

Indexed keywords

ASPARAGINE; DOXORUBICIN; ESTROGEN RECEPTOR; GLUTATHIONE TRANSFERASE; SERINE;

ABCB1 GENE; ADULT; AGED; ARTICLE; BREAST CANCER; CAUCASIAN; CHI SQUARE TEST; DISEASE PREDISPOSITION; EXON; GENE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DOXORUBICIN; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HUMANS; LINKAGE DISEQUILIBRIUM; MIDDLE AGED; MUTATION; NORWAY; ORGANIC ANION TRANSPORTERS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOMBINATION, GENETIC; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33847048615     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328011abaa     Document Type: Article

References (45)

1. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2:48-58.
2. Gilbert L, Elwood LJ, Merino M, Masood S, Barnes R, Steinberg SM, et al. A pilot study of pi-class glutathione S-transferase expression in breast cancer: correlation with estrogen receptor expression and prognosis in node-negative breast cancer. J Clin Oncol 1993; 11:49-58.
3. Molina R, Oesterreich S, Zhou JL, Tandon AK, Clark GM, Allred DC, et al. Glutathione transferase GST pi in breast tumors evaluated by three techniques. Dis Markers 1993; 11:71-82.
4. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 1989; 58:137-171.
5. Johnstone RW, Ruefli AA, Smyth MJ. Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci 2000; 25:1-6.
6. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994; 77:491-502.
7. Wu H, Hait WN, Yang JM. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res 2003; 63:1515-1519.
8. Albermann N, Schmitz-Winnenthal FH, Z'graggen K, Volk C, Hoffmann MM, Haefeli WE, et al. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol 2005; 70:949-958.
9. Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003; 13:481-494.
10. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000; 97:3473-3478.
11. Illmer T, Schuler US, Thiede C, Schwarz UI, Kim RB, Gotthard S, et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 2002; 62:4955-4962.
12. Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 2003; 4:397-410.
13. Tsuchida S, Sato K. Glutathione transferases and cancer. Crit Rev Biochem Mol Biol 1992; 27:337-384.
14. Duvoix A, Schnekenburger M, Delhalle S, Blasius R, Borde-Chiche P, Morceau F, et al. Expression of glutathione S-transferase P1-1 in leukemic cells is regulated by inducible AP-1 binding. Cancer Lett 2004; 216:207-219.
15. Watson MA, Stewart RK, Smith GB, Massey TE, Bell DA. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 1998; 19:275-280.
16. Ambrosone CB, Sweeney C, Coles BF, Thompson PA, McClure GY, Korourian S, et al. Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Res 2001; 61:7130-7135.
17. Davies SM, Bhatia S, Ross JA, Kiffmeyer WR, Gaynon PS, Radloff GA, et al. Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood 2002; 100:67-71.
18. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996; 2:811-814.
19. Geisler S, Lonning PE, Aas T, Johnsen H, Fluge O, Haugen DF, et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001; 61:2505-2512.
20. Langerod A, Bukholm IR, Bregard A, Lonning PE, Andersen TI, Rognum TO, et al. The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev 2002; 11:1684-1688.
21. Hayward JL, Carbone PP, Heusen JC, Kumaoka S, Segaloff A, Rubens RD. Assessment to response to chemotherapy in advanced breast cancer. BR J Cancer 1977; 35:292-298.
22. Page DL, Ellis IO, Elston CW. Histologic grading of breast cancer. Let's do it. Am J Clin Pathol 1995; 103:123-124.
23. Helle SI, Ekse D, Holly JM, Lonning PE. The IGF-system in healthy pre- and postmenopausal women: relations to demographic variables and sex-steroids. J Steroid Biochem Mol Biol 2002; 81:95-102.
24. Andersen TI, Gaustad A, Ottestad L, Farrants GW, Nesland JM, Tveit KM, et al. Genetic alterations of the tumour suppressor gene regions 3p, 11p, 13q, 17p, and 17q in human breast carcinomas. Genes Chromosomes Cancer 1992; 4:113-121.
25. Kristensen V, Andersen TI, Erikstein B, Geitvik G, Skovlund E, Nesland JM, et al. Single tube multiplex polymerase chain reaction genotype analysis of GSTM1, GSTT1 and GSTP1: relation of genotypes to TP53 tumor status and clinicopathological variables in breast cancer patients. Pharmacogenetics 1998; 8:441-447.
26. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69:169-174.
27. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003; 73:1162-1169.
28. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68:978-989.
29. Rozas J, Sanchez-DelBarrio JC, Messeguer X, Rozas R. DnaSP, DNA polymorphism analyses by the coalescent and other methods. Bioinformatics 2003; 19:2496-2497.
30. Abecasis GR, Cookson WO. GOLD: graphical overview of linkage disequilibrium. Bioinformatics 2000; 16:182-183.
31. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21:263-265.
32. Hawley ME, Kidd KK. HAPLO: a program using the EM algorithm to estimate the frequencies of multi-site haplotypes. J Hered 1995; 86:409-411.
33. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002; 70:425-434.
34. Azzaria M, Schurr E, Gros P. Discrete mutations introduced in the predicted nucleotide-binding sites of the mdr1 gene abolish its ability to confer multidrug resistance. Mol Cell Biol 1989; 9:5289-5297.
35. Gudmundsdottir K, Tryggvadottir L, Eyfjord JE. GSTM1, GSTT1, and GSTP1 genotypes in relation to breast cancer risk and frequency of mutations in the p53 gene. Cancer Epidemiol Biomarkers Prev 2001; 10:1169-1173.
36. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70:189-199.
37. Chin KV, Ueda K, Pastan I, Gottesman MM. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 1992; 255:459-462.
38. Zastawny RL, Salvino R, Chen J, Benchimol S, Ling V. The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53. Oncogene 1993; 8:1529-1535.
39. Thottassery JV, Zambetti GP, Arimori K, Schuetz EG, Schuetz JD. p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. Proc Natl Acad Sci U S A 1997; 94:11037-11042.
40. Sampath J, Sun D, Kidd VJ, Grenet J, Gandhi A, Shapiro LH, et al. Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. J Biol Chem 2001; 276:39359-39367.
41. Altuvia S, Stein WD, Goldenberg S, Kane SE, Pastan I, Gottesman MM. Targeted disruption of the mouse mdr1b gene reveals that steroid hormones enhance mdr gene expression. J Biol Chem 1993; 268:27127-27132.
42. Leonessa F, Jacobson M, Boyle B, Lippman J, McGarvey M, Clarke R. Effect of tamoxifen on the multidrug-resistant phenotype in human breast cancer cells: isobologram, drug accumulation, and M(r) 170 000 glycoprotein (gp170) binding studies. Cancer Res 1994; 54:441-447.
43. Ramu A, Fuks Z, Gatt S, Glaubiger D. Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by perhexiline maleate. Cancer Res 1984; 44:144-148.
44. Zampieri L, Bianchi P, Ruff P, Arbuthnot P. Differential modulation by estradiol of P-glycoprotein drug resistance protein expression in cultured MCF7 and T47D breast cancer cells. Anticancer Res 2002; 22:2253-2259.
45. Tang K, Wong LP, Lee EJ, Chong SS, Lee CG. Genomic evidence for recent positive selection at the human MDR1 gene locus. Hum Mol Genet 2004; 13:783-797.